Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein Perforin

A series of novel 5-arylidene-2-thioxoimidazolidin-4-ones were investigated as inhibitors of the lymphocyte-expressed pore-forming protein perforin. Structure–activity relationships were explored through variation of an isoindolinone or 3,4-dihydroisoquinolinone subunit on a fixed 2-thioxoimidazolidin-4-one/thiophene core. The ability of the resulting compounds to inhibit the lytic activity of both isolated perforin protein and perforin delivered in situ by natural killer cells was determined. A number of compounds showed excellent activity at concentrations that were nontoxic to the killer cells, and several were a significant improvement on previous classes of inhibitors, being substantially more potent and soluble. Representative examples showed rapid and reversible binding to immobilized mouse perforin at low concentrations (≤2.5 μM) by surface plasmon resonance and prevented formation of perforin pores in target cells despite effective target cell engagement, as determined by calcium influx studies. Mouse PK studies of two analogues showed T1/2 values of 1.1–1.2 h (dose of 5 mg/kg iv) and MTDs of 60–80 mg/kg (ip).

[1]  J. Trapani,et al.  Rapid and Unidirectional Perforin Pore Delivery at the Cytotoxic Immune Synapse , 2013, The Journal of Immunology.

[2]  Helen R Saibil,et al.  Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. , 2013, Blood.

[3]  Jonathan B. Baell,et al.  Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350, 000 Compounds , 2013, J. Chem. Inf. Model..

[4]  J. Whisstock,et al.  Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. , 2012, Trends in immunology.

[5]  T. Tomašič,et al.  Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation , 2012, Expert opinion on drug discovery.

[6]  J. A. Spicer,et al.  Inhibition of the pore-forming protein perforin by a series of aryl-substituted isobenzofuran-1(3H)-ones. , 2012, Bioorganic & medicinal chemistry.

[7]  Thomas Mendgen,et al.  Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[8]  M. Gütschow,et al.  New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds. , 2011, Bioorganic & medicinal chemistry.

[9]  J. A. Spicer,et al.  Inhibition of the cellular function of perforin by 1-amino-2,4-dicyanopyrido[1,2-a]benzimidazoles. , 2011, Bioorganic & medicinal chemistry.

[10]  Olivia Susanto,et al.  Protection from endogenous perforin: glycans and the C terminus regulate exocytic trafficking in cytotoxic lymphocytes. , 2011, Immunity.

[11]  L. Meijer,et al.  Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. , 2011, Journal of medicinal chemistry.

[12]  K. Kinzler,et al.  Thiazolidinedione-Based PI3Kα Inhibitors: An Analysis of Biochemical and Virtual Screening Methods , 2011, ChemMedChem.

[13]  J. Whisstock,et al.  The structural basis for membrane binding and pore formation by lymphocyte perforin , 2010, Nature.

[14]  A. Fischer,et al.  Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules , 2010, Nature Reviews Immunology.

[15]  Yong-tang Zheng,et al.  Anti HIV-1 agents 5: synthesis and anti-HIV-1 activity of some N-arylsulfonyl-3-acetylindoles in vitro. , 2010, Bioorganic & medicinal chemistry letters.

[16]  J. Whisstock,et al.  Perforin: structure, function, and role in human immunopathology , 2010, Immunological reviews.

[17]  J. Trapani,et al.  The role of perforin and granzymes in diabetes , 2010, Cell Death and Differentiation.

[18]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[19]  J. Trapani,et al.  The battlefield of perforin/granzyme cell death pathways , 2010, Journal of leukocyte biology.

[20]  J. Whisstock,et al.  The molecular basis for perforin oligomerization and transmembrane pore assembly. , 2009, Immunity.

[21]  T. Tomašič,et al.  Rhodanine as a privileged scaffold in drug discovery. , 2009, Current medicinal chemistry.

[22]  J. A. Spicer,et al.  Dihydrofuro[3,4-c]pyridinones as inhibitors of the cytolytic effects of the pore-forming glycoprotein perforin. , 2008, Journal of medicinal chemistry.

[23]  Ashley M Buckle,et al.  A Common Fold Mediates Vertebrate Defense and Bacterial Attack , 2007, Science.

[24]  I. Yaniv,et al.  Pancreatic islets under attack: cellular and molecular effectors. , 2007, Current pharmaceutical design.

[25]  G. Janka Familial and acquired hemophagocytic lymphohistiocytosis , 2006, European Journal of Pediatrics.

[26]  J. Tredger,et al.  Immunosuppression in pediatric solid organ transplantation: Opportunities, risks, and management , 2006, Pediatric transplantation.

[27]  R. Kiesslich,et al.  Drug Insight: novel small molecules and drugs for immunosuppression , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[28]  D. Gjertson,et al.  Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. , 2006, Human immunology.

[29]  A. Chakraborti,et al.  Copper(II) tetrafluoroborate as a novel and highly efficient catalyst for acetal formation , 2005 .

[30]  A. Mori,et al.  Palladium-catalyzed coupling reactions of bromothiophenes at the C-H bond adjacent to the sulfur atom with a new activator system, AgNO3/KF. , 2005, Organic letters.

[31]  B. McManus,et al.  Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. , 2004, The American journal of pathology.

[32]  Mark J. Smyth,et al.  Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.

[33]  R. Bleackley,et al.  Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.

[34]  G. Gribble,et al.  A synthesis of 6,11-disubstituted benzo[b]carbazoles , 2001 .

[35]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[36]  A. Fischer,et al.  Perforin gene defects in familial hemophagocytic lymphohistiocytosis. , 1999, Science.

[37]  Xiaojun Wang,et al.  A significantly improved condition for cyclization of phenethylcarbamates to N-alkylated 3,4-dihydroisoquinolones , 1998 .

[38]  R. Zinkernagel,et al.  Reduced Incidence and Delayed Onset of Diabetes in Perforin-deficient Nonobese Diabetic Mice , 1997, The Journal of experimental medicine.

[39]  Ta‐Jung Lu,et al.  An Efficient Method for the Acetalization of α,β- Unsaturated Aldehydes. , 1995 .

[40]  Ta‐Jung Lu,et al.  An Efficient Method for the Acetalization of .alpha.,.beta.-Unsaturated Aldehydes , 1995 .

[41]  C. Humblet,et al.  Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists. , 1992, Journal of medicinal chemistry.

[42]  P. Lu,et al.  Structure and function of human perforin , 1988, Nature.

[43]  E. Podack Perforin: structure, function, and regulation. , 1992, Current topics in microbiology and immunology.